Bridgewater Associates LP increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 2,211.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 273,839 shares of the biopharmaceutical company's stock after buying an additional 261,992 shares during the period. Bridgewater Associates LP's holdings in Pfizer were worth $7,265,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. M Holdings Securities Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at about $2,144,000. Lafayette Investments Inc. raised its stake in Pfizer by 2.8% in the fourth quarter. Lafayette Investments Inc. now owns 20,758 shares of the biopharmaceutical company's stock worth $551,000 after buying an additional 559 shares in the last quarter. Schwerin Boyle Capital Management Inc. lifted its holdings in Pfizer by 0.5% during the fourth quarter. Schwerin Boyle Capital Management Inc. now owns 719,425 shares of the biopharmaceutical company's stock worth $19,086,000 after buying an additional 3,700 shares during the period. Ontario Teachers Pension Plan Board boosted its position in Pfizer by 61.4% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 62,456 shares of the biopharmaceutical company's stock valued at $1,657,000 after acquiring an additional 23,771 shares in the last quarter. Finally, Rossby Financial LCC bought a new position in shares of Pfizer in the 4th quarter worth $233,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages recently weighed in on PFE. UBS Group dropped their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $31.07.
Check Out Our Latest Stock Report on PFE
Pfizer Stock Performance
Shares of NYSE:PFE traded down $0.12 during trading on Monday, hitting $22.03. 9,095,402 shares of the stock traded hands, compared to its average volume of 40,365,305. The company has a market cap of $124.91 billion, a price-to-earnings ratio of 15.62, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average price of $24.88 and a two-hundred day moving average price of $26.15. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Insider Activity
In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.06% of the company's stock.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
